Call Results
Results of the 2023 JPND Call for “Large Scale Analysis of Omics Data for Drug-Target Finding in Neurodegenerative Diseases”
The eleven projects were recommended for funding* by an independent, international Peer Review Panel based on scientific excellence with input from the JPND advisory board on patient and public involvement. Proposals are presented in alphabetical order according to their acronym.
*Please note this is a provisional decision. The final approval from national funding agencies is still ongoing.
4DPD-Omics
Spatiotemporal transcriptome and proteome analysis of alpha-Synuclein pathology in Parkinson’s disease: Identification of cell type-specific vulnerability and tolerance mechanisms
Coordinator:
Jochen Prehn, Royal College of Surgeons in Ireland, Ireland
Partners:
Niamh Connolly, Royal College of Surgeons in Ireland, Ireland
Donato Di Monte, Deutsches Zentrum für Neurodegenerative Erkrankungen, Germany
Ronald Melki, Centre National de La Recherche Scientifique, France
György Vámosi, Univesity of Debrecen, Hungary
Wilma van de Berg, Amsterdam University Medical Centers, Netherlands
Mauno Vihinen, Lund University, Sweden
AD-PLCG2
Towards druggable targets in Alzheimer’s disease through characterization of PLCG2-related pathways in neurons and microglia
Coordinator:
Jean-Charles Lambert, Institut Pasteur de Lille, France
Partners:
Enrico Glaab, University of Luxembourg, Luxembourg
Gábor Juhász, Biological Research Centre, Hungary
Stefan Lichtenthaler, Technical University of Munich, Germany
Dominik Paquet, Ludwig-Maximilians-University Hospital, Germany
ADPriOMICS
Prioritization of pathways linking aging and Alzheimer’s disease to cognitive decline and dementia
Coordinator:
Alfredo Ramirez, University Hospital Cologne, Germany
Partners:
Dasa Bohaciakova, Masaryk University, Czech Republic
Michael Heneka, University of Luxembourg, Luxembourg
Henne Holstege, Amsterdam UMC, Netherlands
Jean-Charles Lambert, Institut Pasteur de Lille, France
Agustin Ruiz Laza, Fundacio ACE, Spain
Michael Wagner, Rheinische-Friedrich-Wilhelms-Universität Bonn, Germany
CCAD
Deciphering the Chemoproteomics and Chemo transcriptomics of Anti-Alzheimer Drugs for Novel Druggable Target Identification and Biomarkers Development
Coordinator:
Nicolas Sergeant, University Lille, France
Partners:
Sermin Genc, Izmir Biomedicine and Genome Center, Turkey
Michael Heneka, Université du Luxembourg, Luxembourg
Krzysztof Sobczak, Adam Mickiewicz University Poznan, Poland
Charlotte Teunissen, Amsterdam UMC, Netherlands
Joelle Vinh, University Paris VI, France
Ina Vorberg, Deutsches Zentrum für Neurodegenerative Erkrankungen, Germany
Delineating the role of HTT Cis-Variants in the pathogenesis of Huntington disease
Coordinator:
Huu Phuc Nguyen, Ruhr University Bochum, Germany
Partners:
A. Nazli Basak, Koç University School of Medicine, Turkey
Jirí Klempír, Charles University in Prague, Czech Republic
Åsa Petersen, Lund University, Sweden
Mahmoud Pouladi, University of British Columbia, Canada
MetaboAD
Metabolomics-Driven Biomarker Discovery of Alzheimer’s Disease
Coordinator:
Iben Lundgaard, Lund University (ULUND), Sweden
Partners:
Daniel Globisch, Uppsala University (UU), Sweden
Manuel Menéndez-González, Fundación para la Investigación Sanitaria del Principado de Asturias
(FINBA), Spain
Ines Thiele, University of Galway, Ireland
Tamas Letoha, Pharmacoidea Ltd, Hungary
Rezzan Gülhan, Marmara University School of Medicine (MUSM), Turkey
MyRIAD
(Micro)RNA and informatics approaches for diagnosis, prognosis and treatment of Alzheimer’s disease and Dementia
Coordinator:
Katarzyna Goljanek-Whysall, University of Galway, Ireland
Partners:
Ali Cakmak, Istanbul Technical University, Turkey
Agnieszka Fiszer, Institute of Bioorganic Chemistry Polish Academy of Sciences, Poland
Roberta Ghidoni, IRCCS Istituto Centro San Giovanni di Dio, Italy
Leo Quinlan, University of Galway, Ireland
Prioritizing diagnostics and therapeutics of human prion diseases through integrative omics
Coordinator:
Inga Zerr, University Medical Center Göttingen, Germany
Partners:
Sanne Abeln, Utrecht University, Netherlands
Roberto Chiesa, Istituto di Ricerche Farmacologiche IRCCS, Italy
Markus Glatzel, University Medical Center Hamburg-Eppendorf, Germany
Piero Parchi, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy
Jesus Requena, Instituto de Investigación Sanitaria de Santiago de Compostela, Spain
Beata Katarzyna Sikorska, Medical University of Lodz, Poland
Unraveling the Role of SMN in Nucleolar Homeostasis and Potential Implications for Spinal Muscular Atrophy
Coordinator:
Giuseppina Giglia-Mari, Lyon University, France
Partners:
Jocelyn Côté, University of Ottawa, Canada
Denis Mottet, University of Liege, Belgium
alpha-Synuclein OMICS to identify Drug-targets
Coordinator:
Günter Höglinger, Ludwig-Maximilians-Universität München, Germany
Partners:
György Dormán, TargetEx Ltd., Hungary
Matthias Höllerhage, Medizinische Hochschule Hannover, Germany
Jeanine Houwing-Duistermaat, Radboud University, Netherlands
Thierry Langer, University of Vienna, Austria
Jörg Tost, Centre National de Recherche en Génomique Humaine (CNRGH), France
WesternND
Targeting Western Diet-Induced Neurodegeneration
Coordinator:
Eike Latz, University Hospital Bonn, Germany
Partners:
Wilson Abdo, Radboud University Medical Center, Netherlands
Florent Ginhoux, Gustave Roussy Hospital, France
Roisin McManus, Deutsches Zentrum für Neurodegenerative Erkrankungen, Germany
Musa Mhlanga, Radboud University Medical Center, Netherlands